CA2936467A1 - Hydroxy formamide derivatives and their use - Google Patents

Hydroxy formamide derivatives and their use Download PDF

Info

Publication number
CA2936467A1
CA2936467A1 CA2936467A CA2936467A CA2936467A1 CA 2936467 A1 CA2936467 A1 CA 2936467A1 CA 2936467 A CA2936467 A CA 2936467A CA 2936467 A CA2936467 A CA 2936467A CA 2936467 A1 CA2936467 A1 CA 2936467A1
Authority
CA
Canada
Prior art keywords
methyl
hydroxyformamido
furan
heptanamido
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2936467A
Other languages
English (en)
French (fr)
Inventor
Sarah E. Dowdell
Hilary Schenck Eidam
Mark ELBAN
Ryan Michael Fox
Marlys Hammond
Mark A. Hilfiker
Tram H. Hoang
Lara S. Kallander
Brian Griffin Lawhorn
Sharada Manns
Joanne Philp
David G. Washburn
Guosen Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CA2936467A1 publication Critical patent/CA2936467A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
CA2936467A 2014-01-10 2015-01-09 Hydroxy formamide derivatives and their use Abandoned CA2936467A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925848P 2014-01-10 2014-01-10
US61/925,848 2014-01-10
PCT/IB2015/050179 WO2015104684A1 (en) 2014-01-10 2015-01-09 Hydroxy formamide derivatives and their use

Publications (1)

Publication Number Publication Date
CA2936467A1 true CA2936467A1 (en) 2015-07-16

Family

ID=52440747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936467A Abandoned CA2936467A1 (en) 2014-01-10 2015-01-09 Hydroxy formamide derivatives and their use

Country Status (21)

Country Link
US (2) US10450288B2 (enExample)
EP (1) EP3092233A1 (enExample)
JP (2) JP2017507915A (enExample)
KR (1) KR20160106684A (enExample)
CN (2) CN106103431B (enExample)
AU (1) AU2015205370B2 (enExample)
BR (1) BR112016016130A2 (enExample)
CA (1) CA2936467A1 (enExample)
CL (1) CL2016001746A1 (enExample)
CR (1) CR20160316A (enExample)
DO (1) DOP2016000170A (enExample)
EA (1) EA031654B1 (enExample)
IL (1) IL246653A0 (enExample)
MA (1) MA39171A1 (enExample)
MX (1) MX2016009064A (enExample)
PE (1) PE20160998A1 (enExample)
PH (1) PH12016501349A1 (enExample)
SG (1) SG11201605539SA (enExample)
TW (1) TW201620887A (enExample)
UA (1) UA118278C2 (enExample)
WO (1) WO2015104684A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103431B (zh) * 2014-01-10 2019-03-15 葛兰素史密斯克莱知识产权（第2 号）有限公司 羟基甲酰胺衍生物及其用途
WO2017006295A1 (en) * 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use
EP3319961A1 (en) 2015-07-09 2018-05-16 Glaxosmithkline Intellectual Property (No. 2) Limited N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
US9862675B1 (en) * 2017-07-05 2018-01-09 King Fahd University Of Petroleum And Minerals Method of N-formylating amines with a phosphonic anhydride
EP3886798B1 (en) 2018-11-29 2026-01-28 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
BR112023001646A2 (pt) * 2020-07-31 2023-04-04 Glaxosmithkline Ip Dev Ltd Proteínas de ligação a bmp1, tll1 e/ou tll2, método para a produção das mesmas, sequência polinucleotídica, vetor de expressão, célula hospedeira recombinante, composição farmacêutica e usos das ditas proteínas ou composição para tratar uma doença ou distúrbio relacionado à fibrose e promover o crescimento muscular e/ou melhorar a função muscular
US12606573B2 (en) 2020-10-07 2026-04-21 VenatoRx Pharmaceuticals, Inc. Process for boron-containing compounds
CN114195638B (zh) * 2021-12-28 2023-07-14 青岛科技大学 一种邻羟基苯甲酸苯酯的制备方法
CN114230463B (zh) * 2021-12-28 2024-06-21 青岛科技大学 一种邻羟基苯甲酸苯酯的后处理方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6451968B1 (en) 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US6228982B1 (en) 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
GB9311386D0 (en) 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
GB2289677A (en) 1993-12-06 1995-11-29 Pna Diagnostics As Labelling of nucleic acid analogue-peptide chimerae
GB2285445A (en) 1993-12-06 1995-07-12 Pna Diagnostics As Protecting nucleic acids and methods of analysis
AU3999495A (en) 1994-10-06 1996-05-02 Buchardt, Dorte Peptide nucleic acid conjugates
AU3288497A (en) 1996-05-30 1998-01-05 Wisconsin Alumni Research Foundation Mammalian tolloid-like gene and protein
US6008017A (en) 1997-01-02 1999-12-28 Smithkline Beecham Corporation Human cardiac/brain tolloid-like protein
US6037139A (en) 1997-06-03 2000-03-14 Wisconsin Alumni Research Foundation System for assaying modulators of procollagen maturation
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0922702A1 (de) 1997-12-13 1999-06-16 Roche Diagnostics GmbH Neue Azulenderivate und diese enthaltende Arzneimittel
JP2002510487A (ja) 1998-04-03 2002-04-09 ウイスコンシン アラムニ リサーチ ファンデーション 哺乳類のｔｏｌｌｏｉｄ様遺伝子及びタンパク質
DE19850072A1 (de) 1998-10-30 2000-05-04 Bayer Ag Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen
TR200101663T2 (tr) * 1998-12-10 2001-11-21 F.Hoffmann-La Roche Ag Pro-kollajen c-proteinaz inhibitörleri
HRP20010443A2 (en) 1998-12-22 2002-06-30 Hoffmann La Roche Sulfonamide hydroxamates
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2382030A1 (en) 1999-09-01 2001-03-08 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
GB9930570D0 (en) 1999-12-23 2000-02-16 Pfizer Ltd Therapy
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001095897A1 (en) 2000-06-15 2001-12-20 University Of Kentucky Research Foundation Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
WO2002026696A1 (en) 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US20050147602A1 (en) 2000-10-19 2005-07-07 Maine Medical Center Research Institute Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix
US6630325B1 (en) 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
GB0031321D0 (en) 2000-12-21 2001-02-07 Pfizer Ltd Treatment
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
GB0108097D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6821972B2 (en) * 2001-03-30 2004-11-23 Pfizer Inc. 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US20030087273A1 (en) 2001-06-29 2003-05-08 Holzmayer Tanya A. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
DE10134243A1 (de) 2001-07-14 2003-03-27 Burchardt Elmar Reinhold Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen
DK1442024T3 (da) 2001-11-01 2008-06-30 Janssen Pharmaceutica Nv Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorer
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2003232115A1 (en) 2002-05-13 2003-11-11 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
JP4486892B2 (ja) * 2002-12-11 2010-06-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ペプチドデホルミラーゼ阻害剤
US20060240014A1 (en) 2003-06-03 2006-10-26 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
US7332485B2 (en) 2003-07-08 2008-02-19 Smithkline Beecham Corp Peptide deformylase inhibitors
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
WO2006057951A2 (en) 2004-11-22 2006-06-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
RS52193B (sr) 2004-12-21 2012-10-31 Merck Serono Sa. Ciklični derivati sulfonil amina i njihova upotreba
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
WO2007006858A2 (en) 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP1951687B1 (en) * 2005-11-24 2011-08-24 Merck Serono SA N-hydroxyamide derivatives and use thereof
CA2829865A1 (en) 2006-07-21 2008-01-24 Genera Istrazivanja D.O.O. Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
WO2008024767A2 (en) 2006-08-21 2008-02-28 Wisconsin Alumni Research Foundation Method and composition for treating a fibrotic disorder
EP1932907A1 (en) 2006-12-12 2008-06-18 Novartis AG Crystal structure of the catalytic domain of tolloid-like protease 1 and uses thereof
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
WO2009097893A1 (en) 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
WO2013163479A1 (en) 2012-04-25 2013-10-31 General Istrazivanja D.O.O. Methods and compositions for treating and diagnosing acute myocardial infarction
CN106103431B (zh) * 2014-01-10 2019-03-15 葛兰素史密斯克莱知识产权（第2 号）有限公司 羟基甲酰胺衍生物及其用途
WO2017006295A1 (en) 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use
EP3319961A1 (en) 2015-07-09 2018-05-16 Glaxosmithkline Intellectual Property (No. 2) Limited N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors

Also Published As

Publication number Publication date
BR112016016130A2 (pt) 2017-08-08
MX2016009064A (es) 2017-01-23
MA39171A1 (fr) 2017-07-31
WO2015104684A1 (en) 2015-07-16
PE20160998A1 (es) 2016-10-26
EA031654B1 (ru) 2019-02-28
EP3092233A1 (en) 2016-11-16
CN106103431A (zh) 2016-11-09
UA118278C2 (uk) 2018-12-26
AU2015205370A1 (en) 2016-07-21
DOP2016000170A (es) 2016-10-30
US20160340328A1 (en) 2016-11-24
US10450288B2 (en) 2019-10-22
TW201620887A (zh) 2016-06-16
SG11201605539SA (en) 2016-08-30
IL246653A0 (en) 2016-08-31
CN109970797A (zh) 2019-07-05
CL2016001746A1 (es) 2017-06-02
AU2015205370B2 (en) 2017-11-30
PH12016501349A1 (en) 2016-08-15
US20200095217A1 (en) 2020-03-26
CN106103431B (zh) 2019-03-15
JP2017507915A (ja) 2017-03-23
CR20160316A (es) 2016-09-19
KR20160106684A (ko) 2016-09-12
EA201691412A1 (ru) 2016-12-30
JP2020011968A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US10450288B2 (en) Hydroxy formamide derivatives and their use
JP3155536B2 (ja) アミノブタン酸誘導体
JP6915003B2 (ja) ヒト血漿カリクレイン阻害剤
KR101937496B1 (ko) 케모카인 수용체 조절제로서의 인 유도체
RU2163232C2 (ru) Карбоксамиды, способ их получения и фармацевтическая композиция
EP2598486B1 (en) Bicyclic acetyl-coa carboxylase inhibitors
US8415378B2 (en) Isoxazol-3(2H)-one analogs as therapeutic agents
JP2023539101A (ja) ジペプチジルペプチダーゼ１の阻害剤として作用するニトリル誘導体及びその使用
AU2017336523A1 (en) Calpain modulators and therapeutic uses thereof
JPWO1999019296A1 (ja) アミノブタン酸誘導体
EP0936216A1 (en) Novel acetamide derivatives and protease inhibitors
WO2013174937A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
TWI796714B (zh) 人類血漿激肽釋放酶抑制劑
JP2010001298A (ja) 血漿カルボキシペプチダーゼｂインヒビター
CA2925291A1 (en) Substituted phenylalanine derivatives
WO2017006295A1 (en) Hydroxy formamide derivatives and their use
UA129065C2 (uk) Аміноарильна похідна сполука, корисна як інгібітор діацилгліцеролацилтрансферази-2, та її використання
US20180362485A1 (en) N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS
JP3470692B2 (ja) アミノブタン酸誘導体
JPH0853415A (ja) β−アラニン誘導体およびその製造法
NZ752865B2 (en) Calpain modulators and therapeutic uses thereof
JP2003212831A (ja) アミノブタン酸誘導体
JPH10306092A (ja) ２−ピペラジノン−１−酢酸誘導体及びその用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831